{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:09:04Z","timestamp":1791925744225,"version":"4.3.4"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12149-018-1292-6","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:24:44Z","timestamp":1534724684000},"page":"583-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["SPECT and PET imaging in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"32","author":[{"given":"Varvara","family":"Valotassiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Malamitsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Papatriantafyllou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthimios","family":"Dardiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsougos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Psimadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiria","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hadjigeorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368:387\u2013403.","journal-title":"Lancet"},{"key":"1292_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jalz.2010.01.009","volume":"6","author":"Alzheimer","year":"2010","unstructured":"Alzheimer\u2019s Association. 2010 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2010;6:158\u201394.","journal-title":"Alzheimers Dement"},{"key":"1292_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/archneurol.2009.106","volume":"66","author":"ST Farias","year":"2009","unstructured":"Farias ST, Mungas D, Reed BR, Harvey D, De Carli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66:1151\u20137.","journal-title":"Arch Neurol"},{"key":"1292_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"1292_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association work groups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1292_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1148\/radiol.12110433","volume":"263","author":"CR Jack Jr","year":"2012","unstructured":"Jack CR Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology. 2012;263:344\u201361.","journal-title":"Radiology"},{"key":"1292_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/157488408784293679","volume":"3","author":"V Valotassiou","year":"2008","unstructured":"Valotassiou V, Wozniak G, Sifakis N, Demakopoulos N, Georgoulias P. Radiopharmaceuticals in neurological and psychiatric disorders. Curr Clin Pharmacol. 2008;3:99\u2013107.","journal-title":"Curr Clin Pharmacol"},{"key":"1292_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2174\/156720510792231757","volume":"7","author":"V Valotassiou","year":"2010","unstructured":"Valotassiou V, Archimandritis S, Sifakis N, Papatriantafyllou J, Georgoulias P. Alzheimer\u2019s disease: SPECT and PET tracers for beta-amyloid imaging. Curr Alzheimer Res. 2010;7:477\u201386.","journal-title":"Curr Alzheimer Res"},{"key":"1292_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fnhum.2015.00249","volume":"9","author":"W Mier","year":"2015","unstructured":"Mier W, Mier D. Advantages in functional imaging of the brain. Front Hum Neurosci. 2015;9:249.","journal-title":"Front Hum Neurosci"},{"key":"1292_CR10","first-page":"240","volume":"7","author":"A Villringer","year":"1995","unstructured":"Villringer A, Dirnagl U. Coupling of brain activity and cerebral blood flow: basis of functional neuroimaging. Cerebrovasc Brain Metab Rev. 1995;7:240\u201376.","journal-title":"Cerebrovasc Brain Metab Rev"},{"key":"1292_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3233\/JAD-150068","volume":"47","author":"V Valotassiou","year":"2015","unstructured":"Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos I, Psimadas D, et al. Clinical evaluation of brain perfusion SPECT with Brodmann areas mapping in early diagnosis of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2015;47:773\u201385.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1292_CR12","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1097\/MNM.0b013e3283599983","volume":"33","author":"V Valotassiou","year":"2012","unstructured":"Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos I, Kapsalaki E, et al. Perfusion SPECT studies with mapping of Brodmann areas in differentiating Alzheimer\u2019s disease from frontotemporal degeneration syndromes. Nucl Med Commun. 2012;33:1267\u201376.","journal-title":"Nucl Med Commun"},{"key":"1292_CR13","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/brain\/awm177","volume":"130","author":"NL Foster","year":"2007","unstructured":"Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer\u2019s disease. Brain. 2007;130:2616\u201335.","journal-title":"Brain"},{"key":"1292_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1055\/s-0028-1083695","volume":"28","author":"P Vitali","year":"2008","unstructured":"Vitali P, Migliaccio R, Agosta F, Rosen HJ, Geschwind MD. Neuroimaging in dementia. Semin Neurol. 2008;28:467\u201383.","journal-title":"Semin Neurol"},{"key":"1292_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2967\/jnumed.107.045385","volume":"49","author":"L Mosconi","year":"2008","unstructured":"Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer\u2019s disease, and other dementias. J Nucl Med. 2008;49:390\u20138.","journal-title":"J Nucl Med"},{"key":"1292_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3233\/JAD-2011-110458","volume":"26","author":"LM Bloudek","year":"2011","unstructured":"Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer\u2019s disease. J Alzheimers Dis. 2011;26:627\u201345.","journal-title":"J Alzheimers Dis"},{"key":"1292_CR17","doi-asserted-by":"publisher","first-page":"33182","DOI":"10.1371\/journal.pone.0033182","volume":"7","author":"D Zhang","year":"2012","unstructured":"Zhang D, Shen D, Alzheimer\u2019s Disease Neuroimaging Initiative. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One. 2012;7:33182.","journal-title":"PLoS One"},{"key":"1292_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1212\/WNL.0b013e31829d86e8","volume":"81","author":"GB Frisoni","year":"2013","unstructured":"Frisoni GB, Bocchetta M, Ch\u00e9telat G, Rabinovici GD, de Leon MJ, Kaye J, ISTAART\u2019s NeuroImaging Professional Interest Area, et al. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81:487\u2013500.","journal-title":"Neurology"},{"key":"1292_CR19","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1007\/s00259-017-3761-x","volume":"44","author":"M Pagani","year":"2017","unstructured":"Pagani M, Nobili F, Morbelli S, Arnaldi D, Giuliani A, \u00d6berg J, et al. Early identification of MCI converting to AD: a FDG PET study. Eur J Nucl Med Mol Imaging. 2017;44:2042\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF00173036","volume":"21","author":"PR Talbot","year":"1994","unstructured":"Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ. Choice of reference region in the quantification of single-photon emission tomography in primary degenerative dementia. Eur J Nucl Med. 1994;21:503\u20138.","journal-title":"Eur J Nucl Med"},{"key":"1292_CR21","first-page":"134153","volume-title":"Nuclear medicine in clinical diagnosis and treatment","author":"PD Acton","year":"2004","unstructured":"Acton PD. Image analysis in brain SPECT and PET. In: Ell PJ, Gambhir S, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd edition. London: Churchill Livingstone; 2004. p.\u00a01341\u201353.","edition":"3"},{"key":"1292_CR22","first-page":"731","volume":"28","author":"H Matsuda","year":"2007","unstructured":"Matsuda H, Mizumura S, Nagao T, Ota T, Iizuka T, Nemoto K, et al. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol. 2007;28:731\u20136.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1292_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351\u20137.","journal-title":"Neurobiol Aging"},{"key":"1292_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.mibio.2003.09.010","volume":"5","author":"ED Agdeppa","year":"2003","unstructured":"Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, et al. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer\u2019s disease. Mol Imaging Biol. 2003;5:404\u201317.","journal-title":"Mol Imaging Biol"},{"key":"1292_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"1292_CR26","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta amyloid burden in aging and dementia. Neurology. 2007;68:1718\u201325.","journal-title":"Neurology"},{"key":"1292_CR27","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ana.23633","volume":"72","author":"DM Niedowicz","year":"2012","unstructured":"Niedowicz DM, Beckett TL, Matveev S, Weidner AM, Baig I, Kryscio RJ, et al. Pittsburgh compound b and the postmortem diagnosis of Alzheimer\u2019s disease. Ann Neurol. 2012;72:564\u201370.","journal-title":"Ann Neurol"},{"key":"1292_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-121927","volume":"35","author":"H Cho","year":"2013","unstructured":"Cho H, Seo SW, Kim JH, Suh MK, Lee JH, Choe YS, et al. Amyloid deposition in early onset versus late onset Alzheimer\u2019s disease. J Alzheimers Dis. 2013;35:813\u201321.","journal-title":"J Alzheimers Dis"},{"key":"1292_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1212\/01.wnl.0000259035.98480.ed","volume":"68","author":"GD Rabinovici","year":"2007","unstructured":"Rabinovici GD, Furst AJ, O\u2019Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205\u201312.","journal-title":"Neurology"},{"key":"1292_CR30","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456\u201365.","journal-title":"Neurobiol Aging"},{"key":"1292_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/brain\/awt286","volume":"137","author":"YY Lim","year":"2014","unstructured":"Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer\u2019s disease. Brain. 2014;137:221\u201331.","journal-title":"Brain"},{"key":"1292_CR32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, N\u00e5gren K, et al. Conversion of amyloid positive and negative MCI to AD over 3\u00a0years: an 11C-PIB PET study. Neurology. 2009;73:754\u201360.","journal-title":"Neurology"},{"key":"1292_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Pike KE, Ch\u00e9telat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181\u201392.","journal-title":"Ann Neurol"},{"key":"1292_CR34","first-page":"82","volume":"10","author":"T Grimmer","year":"2013","unstructured":"Grimmer T, Wutz C, Drzezga A, F\u00f6rster S, F\u00f6rstl H, Ortner M, et al. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res. 2013;10:82\u20135.","journal-title":"Curr Alzheimer Res"},{"key":"1292_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MD.0000000000000150","volume":"93","author":"Y Ma","year":"2014","unstructured":"Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis [Corrected]. Medicine (Baltimore). 2014;93:150.","journal-title":"Medicine (Baltimore)"},{"key":"1292_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.112.109009","volume":"54","author":"SM Landau","year":"2013","unstructured":"Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70\u20137.","journal-title":"J Nucl Med"},{"key":"1292_CR37","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jnnp-2012-302548","volume":"83","author":"DA Wolk","year":"2012","unstructured":"Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer\u2019s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83:923\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1292_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378.","journal-title":"Lancet Neurol"},{"key":"1292_CR39","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/mp.2014.9","volume":"19","author":"PM Doraiswamy","year":"2014","unstructured":"Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19:1044\u201351.","journal-title":"Mol Psychiatry"},{"key":"1292_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/NEN.0000000000000028","volume":"73","author":"BN Dugger","year":"2014","unstructured":"Dugger BN, Clark CM, Serrano G, Mariner M, Bedell BJ, Coleman RE, et al. Neuropathologic heterogeneity does not impair florbetapir positron emission tomography postmortem correlates. J Neuropathol Exp Neurol. 2014;73:72\u201380.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1292_CR41","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1007\/s00259-011-1821-1","volume":"38","author":"H Barthel","year":"2011","unstructured":"Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain \u03b2-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer\u2019s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38:1702\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR42","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424\u201335.","journal-title":"Lancet Neurol"},{"key":"1292_CR43","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid plaques in Alzheimer disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374.","journal-title":"Alzheimers Dement"},{"key":"1292_CR44","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210\u20137.","journal-title":"J Nucl Med"},{"key":"1292_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/alzrt158","volume":"5","author":"K Ong","year":"2013","unstructured":"Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Ch\u00e9telat G, Raniga P, et al. (18)F-florbetaben A\u03b2 imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5:4.","journal-title":"Alzheimers Res Ther"},{"key":"1292_CR46","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:290\u2013300.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR47","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/arclin\/act047","volume":"28","author":"K Duff","year":"2013","unstructured":"Duff K, Foster NL, Dennett K, Hammers DB, Zollinger LV, Christian PE, et al. Amyloid deposition and cognition in older adults: the effects of premorbid intellect. Arch Clin Neuropsychol. 2013;28:665\u201371.","journal-title":"Arch Clin Neuropsychol"},{"key":"1292_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","volume":"43","author":"E Morris","year":"2016","unstructured":"Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43:374\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR49","doi-asserted-by":"publisher","first-page":"1006-e2536","DOI":"10.1016\/j.neurobiolaging.2011.10.001","volume":"33","author":"NL Marchant","year":"2012","unstructured":"Marchant NL, Reed BR, DeCarli CS, Madison CM, Weiner MW, Chui HC, et al. Cerebrovascular disease, \u03b2-amyloid, and cognition in aging. Neurobiol Aging. 2012;33:1006-e25\u201336.","journal-title":"Neurobiol Aging"},{"key":"1292_CR50","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","volume":"31","author":"CC Rowe","year":"2010","unstructured":"Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275\u201383.","journal-title":"Neurobiol Aging"},{"key":"1292_CR51","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3233\/JAD-2010-100222","volume":"21","author":"S Hatashita","year":"2010","unstructured":"Hatashita S, Yamasaki H. Clinically different stages of Alzheimer\u2019s disease associated by amyloid deposition with 11C-PIB PET imaging. J Alzheimers Dis. 2010;21:995\u20131003.","journal-title":"J Alzheimers Dis"},{"key":"1292_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40120-014-0022-9","volume":"3","author":"D Richards","year":"2014","unstructured":"Richards D, Sabbagh MN. Florbetaben for PET imaging of beta amyloid plaques in the brain. Neurol Ther. 2014;3:79\u201388.","journal-title":"Neurol Ther"},{"key":"1292_CR53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.neuint.2008.12.016","volume":"54","author":"MM Svedberg","year":"2009","unstructured":"Svedberg MM, Hall H, Hellstr\u00f6m-Lindahl E, Estrada S, Guan Z, Nordberg A, et al. [11C]PIB-amyloid binding and levels of A\u03b240 and A\u03b242 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54:347\u201357.","journal-title":"Neurochem Int"},{"key":"1292_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315.","journal-title":"Alzheimers Dement"},{"key":"1292_CR55","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2967\/jnumed.115.171595","volume":"57","author":"CC Rowe","year":"2016","unstructured":"Rowe CC, Jones G, Dor\u00e9 V, Pejoska S, Margison L, Mulligan RS, et al. Standardized expression of 18F-NAV4694 and 11C-PiB \u03b2-amyloid PET results with the Centiloid Scale. J Nucl Med. 2016;57:1233\u20137.","journal-title":"J Nucl Med"},{"key":"1292_CR56","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, Dor\u00e9 V, Jones G. 18F-Florbetaben PET beta-amyloid binding expressed in centiloids. Eur J Nucl Med Mol Imaging. 2017;44:2053\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s13311-016-0474-y","volume":"14","author":"K Anand","year":"2017","unstructured":"Anand K, Sabbagh M. Amyloid imaging: poised for integration into medical practice. Neurotherapeutics. 2017;14:54\u201361.","journal-title":"Neurotherapeutics"},{"key":"1292_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-015-0090-6","volume":"5","author":"BH Yousefi","year":"2015","unstructured":"Yousefi BH, von Reutern B, Scher\u00fcbl D, Manook A, Schwaiger M, Grimmer T, et al. FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI Res. 2015;5:20.","journal-title":"EJNMMI Res"},{"key":"1292_CR59","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2967\/jnumed.114.146944","volume":"56","author":"CJ Chen","year":"2015","unstructured":"Chen CJ, Bando K, Ashino H, Taguchi K, Shiraishi H, Shima K, et al. In vivo SPECT imaging of amyloid-\u03b2 deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer\u2019s disease. J Nucl Med. 2015;56:120\u20136.","journal-title":"J Nucl Med"},{"key":"1292_CR60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/brain\/awv305","volume":"139","author":"Y Maya","year":"2016","unstructured":"Maya Y, Okumura Y, Kobayashi R, Onishi T, Shoyama Y, Barret O, et al. Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-\u03b2. Brain. 2016;139:193\u2013203.","journal-title":"Brain"},{"key":"1292_CR61","first-page":"254","volume":"10","author":"VL Villemagne","year":"2014","unstructured":"Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheimers Dement. 2014;10:254\u201364.","journal-title":"Alzheimers Dement"},{"key":"1292_CR62","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.neuroimage.2012.01.066","volume":"60","author":"KN Schafer","year":"2012","unstructured":"Schafer KN, Kim S, Matzavinos A, Kuret J. Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer\u2019s disease: a simulation study. Neuroimage. 2012;60:1724\u201333.","journal-title":"Neuroimage"},{"key":"1292_CR63","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ymeth.2017.08.003","volume":"130","author":"GN Bischof","year":"2017","unstructured":"Bischof GN, Endepols H, van Eimeren T, Drzezga A. Tau-imaging in neurodegeneration. Methods. 2017;130:114\u201323.","journal-title":"Methods"},{"key":"1292_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"14","author":"VL Villemagne","year":"2015","unstructured":"Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114\u201324.","journal-title":"Lancet Neurol"},{"key":"1292_CR65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrn2967","volume":"12","author":"LM Ittner","year":"2011","unstructured":"Ittner LM, Gotz J. Amyloid-beta and tauea toxic pas de deux in Alzheimer\u2019s disease. Nat Rev Neurosci. 2011;12:65\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"1292_CR66","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1017\/cjn.2014.15","volume":"41","author":"ER Zimmer","year":"2014","unstructured":"Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P. Developments in tau PET imaging. Can J Neurol Sci. 2014;41:547\u201353.","journal-title":"Can J Neurol Sci"},{"key":"1292_CR67","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awr038","volume":"134","author":"MT Fodero-Tavoletti","year":"2011","unstructured":"Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer\u2019s disease. Brain. 2011;134:1089\u2013100.","journal-title":"Brain"},{"key":"1292_CR68","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00259-013-2681-7","volume":"41","author":"VL Villemagne","year":"2014","unstructured":"Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:816\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR69","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","volume":"54","author":"N Okamura","year":"2013","unstructured":"Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420\u20137.","journal-title":"J Nucl Med"},{"key":"1292_CR70","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/brain\/awu064","volume":"137","author":"N Okamura","year":"2014","unstructured":"Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer\u2019s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137:1762\u201371.","journal-title":"Brain"},{"key":"1292_CR71","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00259-015-3035-4","volume":"42","author":"R Harada","year":"2015","unstructured":"Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2015;42:1052\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR72","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40478-015-0220-4","volume":"3","author":"L Lemoine","year":"2015","unstructured":"Lemoine L, Saint-Aubert L, Marutle A, Antoni G, Eriksson JP, Ghetti B, et al. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40.","journal-title":"Acta Neuropathol Commun"},{"key":"1292_CR73","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","volume":"43","author":"K Chiotis","year":"2016","unstructured":"Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, et al. Imaging in-vivo tau pathology in Alzheimer\u2019s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging. 2016;43:1686\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR74","doi-asserted-by":"publisher","first-page":"e0158460","DOI":"10.1371\/journal.pone.0158460","volume":"11","author":"SN Lockhart","year":"2016","unstructured":"Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, et al. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer\u2019s disease patients measured using [18F] THK-5351. PLoS One. 2016;11:e0158460.","journal-title":"PLoS One"},{"key":"1292_CR75","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/jlcr.3133","volume":"57","author":"T Tago","year":"2014","unstructured":"Tago T, Furumoto S, Okamura N, Harada R, Ishikawa Y, Arai H, et al. Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. J Label Compd Radiopharm. 2014;57:18\u201324.","journal-title":"J Label Compd Radiopharm"},{"key":"1292_CR76","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","volume":"34","author":"DT Chien","year":"2013","unstructured":"Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457\u201368.","journal-title":"J Alzheimers Dis"},{"key":"1292_CR77","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-130098","volume":"38","author":"DT Chien","year":"2014","unstructured":"Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171\u201384.","journal-title":"J Alzheimers Dis"},{"key":"1292_CR78","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jalz.2013.08.003","volume":"9","author":"M Mintun","year":"2013","unstructured":"Mintun M, Schwarz A, Joshi A, Shcherbinin S, Chien D, Elizarov A, et al. Exploratory analyses of regional human brain distribution of the PET tau tracer F18- labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer\u2019s disease. Alzheimers Dement. 2013;9:842.","journal-title":"Alzheimers Dement"},{"key":"1292_CR79","first-page":"748","volume":"140","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Devous Sr MD, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748\u201363.","journal-title":"Brain"},{"key":"1292_CR80","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.114.139550","volume":"55","author":"H Hashimoto","year":"2014","unstructured":"Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med. 2014;55:1532\u20138.","journal-title":"J Nucl Med"},{"key":"1292_CR81","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2967\/jnumed.115.160127","volume":"56","author":"Y Kimura","year":"2015","unstructured":"Kimura Y, Ichise M, Ito H, Shimada H, Ikoma Y, Seki C, et al. PET quantification of tau pathology in human brain with 11C-PBB3. J Nucl Med. 2015;56:1359\u201365.","journal-title":"J Nucl Med"},{"key":"1292_CR82","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","volume":"79","author":"M Maruyama","year":"2013","unstructured":"Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094\u2013108.","journal-title":"Neuron"},{"key":"1292_CR83","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1021\/ml300216t","volume":"3","author":"X Shao","year":"2012","unstructured":"Shao X, Carpenter GM, Desmond TJ, Sherman P, Quesada CA, Fawaz M, et al. Evaluation of [(11)C] N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles. ACS Med Chem Lett. 2012;3:936\u201341.","journal-title":"ACS Med Chem Lett"},{"key":"1292_CR84","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1021\/cn500103u","volume":"5","author":"MV Fawaz","year":"2014","unstructured":"Fawaz MV, Brooks AF, Rodnick ME, Carpenter GM, Shao X, Desmond TJ, et al. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer\u2019s disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. ACS Chem Neurosci. 2014;5:718\u201330.","journal-title":"ACS Chem Neurosci"},{"key":"1292_CR85","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2967\/jnumed.117.196741","volume":"59","author":"M Honer","year":"2018","unstructured":"Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, et al. Preclinical evaluation of 18F-RO6958948, 11C-RO6931643 and 11C-RO6924963 as novel radiotracers for imaging aggregated tau in AD with positron emission tomography. J Nucl Med. 2018;59:675\u201381.","journal-title":"J Nucl Med"},{"key":"1292_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2007.12.004","volume":"118","author":"MK Chen","year":"2008","unstructured":"Chen MK, Guilarte TR. Translocator protein 18\u00a0kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther. 2008;118:1\u201317.","journal-title":"Pharmacol Ther"},{"key":"1292_CR87","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.nurt.2007.04.006","volume":"4","author":"A Cagnin","year":"2007","unstructured":"Cagnin A, Kassiou M, Meikle SR, Banati RB. Positron emission tomography imaging of neuroinflammation. Neurotherapeutics. 2007;4:443\u201352.","journal-title":"Neurotherapeutics"},{"key":"1292_CR88","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/archneurol.2008.511","volume":"66","author":"CA Wiley","year":"2009","unstructured":"Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66:60\u20137.","journal-title":"Arch Neurol"},{"key":"1292_CR89","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2967\/jnumed.106.036764","volume":"48","author":"H Boutin","year":"2007","unstructured":"Boutin H, Chauveau F, Thominiaux C, Gr\u00e9goire MC, James ML, Trebossen R, et al. 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J Nucl Med. 2007;48:573\u201381.","journal-title":"J Nucl Med"},{"key":"1292_CR90","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s00259-009-1353-0","volume":"37","author":"N Van Camp","year":"2010","unstructured":"Van Camp N, Boisgard R, Kuhnast B, Th\u00e9z\u00e9 B, Viel T, Gr\u00e9goire MC, et al. In vivo imaging of neuroinflammation: a comparative study between [(18)F]PBR111, [(11)C]CLINME and [(11)C]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging. 2010;37:962\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR91","doi-asserted-by":"publisher","first-page":"56441","DOI":"10.1371\/journal.pone.0056441","volume":"8","author":"H Boutin","year":"2013","unstructured":"Boutin H, Prenant C, Maroy R, Galea J, Greenhalgh AD, Smigova A, et al. [18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats. PLoS One. 2013;8:56441.","journal-title":"PLoS One"},{"key":"1292_CR92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000070857","volume":"50","author":"JJ Versijpt","year":"2003","unstructured":"Versijpt JJ, Dumont F, Van Laere KJ, Decoo D, Santens P, Audenaert K, et al. Assessment of neuroinflammation and microglial activation in Alzheimer\u2019s disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur Neurol. 2003;50:39\u201347.","journal-title":"Eur Neurol"},{"issue":"12","key":"1292_CR93","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s00259-008-0834-x","volume":"35","author":"N Arlicot","year":"2008","unstructured":"Arlicot N, Katsifis A, Garreau L, Mattner F, Vergote J, Duval S, et al. Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation. Eur J Nucl Med Mol Imaging. 2008;35(12):2203\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR94","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neurobiolaging.2016.04.011","volume":"44","author":"WC Kreisl","year":"2016","unstructured":"Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E, et al. (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer\u2019s disease. Neurobiol Aging. 2016;44:53\u201361.","journal-title":"Neurobiol Aging"},{"key":"1292_CR95","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00259-016-3444-z","volume":"43","author":"C Feeney","year":"2016","unstructured":"Feeney C, Scott G, Raffel J, Roberts S, Coello C, Jolly A, et al. Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain. Eur J Nucl Med Mol Imaging. 2016;43:2201\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR96","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s00259-016-3457-7","volume":"43","author":"R Ahmad","year":"2016","unstructured":"Ahmad R, Postnov A, Bormans G, Versijpt J, Vandenbulcke M, Van Laere K. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43:2219\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1292_CR97","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2967\/jnumed.115.168732","volume":"57","author":"E Rodriguez-Vieitez","year":"2016","unstructured":"Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy A, Sch\u00f6ll M, et al. Comparison of early-phase 11C-deuterium-l-deprenyl and 11C-Pittsburgh compound B PET for assessing brain perfusion in Alzheimer disease. J Nucl Med. 2016;57:1071\u20137.","journal-title":"J Nucl Med"},{"key":"1292_CR98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.110.087031","volume":"53","author":"SF Carter","year":"2012","unstructured":"Carter SF, Sch\u00f6ll M, Almkvist O, Wall A, Engler H, L\u00e5ngstr\u00f6m B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-l-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37\u201346.","journal-title":"J Nucl Med"},{"key":"1292_CR99","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.2967\/jnumed.107.049619","volume":"49","author":"G Esposito","year":"2008","unstructured":"Esposito G, Giovacchini G, Liow JS, Bhattacharjee AK, Greenstein D, Schapiro M, et al. Imaging neuroinflammation in Alzheimer\u2019s disease with radiolabeled arachidonic acid and PET. J Nucl Med. 2008;49:1414\u201321.","journal-title":"J Nucl Med"},{"key":"1292_CR100","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.plefa.2012.05.003","volume":"88","author":"SI Rapoport","year":"2013","unstructured":"Rapoport SI. Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo. Prostaglandins Leukot Essent Fatty Acids. 2013;88:79\u201385.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"1292_CR101","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-420170-5.00002-7","volume":"122","author":"MK Sun","year":"2014","unstructured":"Sun MK, Alkon DL. The \u2018memory kinases\u2019: roles of PKC isoforms in signal processing and memory formation. Prog Mol Biol Transl Sci. 2014;122:31\u201359.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"1292_CR102","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.bmcl.2011.01.100","volume":"21","author":"M Wang","year":"2011","unstructured":"Wang M, Xu L, Gao M, Miller KD, Sledge GW, Zheng QH. [11C] Enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C. Bioorg Med Chem Lett. 2011;21:1649\u201353.","journal-title":"Bioorg Med Chem Lett"},{"key":"1292_CR103","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.neurobiolaging.2015.05.020","volume":"36","author":"C Chiu","year":"2015","unstructured":"Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer\u2019s disease: preliminary observations. Neurobiol Aging. 2015;36:2475\u201382.","journal-title":"Neurobiol Aging"},{"key":"1292_CR104","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/gps.4338","volume":"30","author":"H Shimada","year":"2015","unstructured":"Shimada H, Hirano S, Sinotoh H, Ota T, Tanaka N, Sato K, et al. Dementia with Lewy bodies can be well-differentiated from Alzheimer\u2019s disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study. Int J Geriatr Psychiatry. 2015;30:1105\u201313.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1292_CR105","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/WAD.0b013e3182222bc0","volume":"26","author":"M Kasuya","year":"2012","unstructured":"Kasuya M, Meguro K, Okamura N, Funaki Y, Ishikawa H, Tanaka N, et al. Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study. Alzheimer Dis Assoc Disord. 2012;26:113\u20138.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1292_CR106","doi-asserted-by":"publisher","first-page":"983","DOI":"10.4155\/fmc-2017-0023","volume":"9","author":"S Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez S, Giglio J, Reyes AL, Dami\u00e1n A, P\u00e9rez C, P\u00e9rez DI, et al. 3-(Benzyloxy)-1-(5-[18F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. Future Med Chem. 2017;9:983\u201394.","journal-title":"Future Med Chem"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-018-1292-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1292-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1292-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T07:36:20Z","timestamp":1650094580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-018-1292-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":106,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1007\/s12149-018-1292-6","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No potential conflicts of interest were disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}